Synergistic effect of JQ1 and rapamycin for treatment of human osteosarcoma. Issue 9 (30th October 2014)

• Record Type: Journal Article
• Authors: Lee, Dhong Hyun; Qi, Jun; Bradner, James E.; Said, Jonathan W.; Doan, Ngan B.; Forscher, Charles; Yang, Henry; Koeffler, H. Phillip
• Is Part Of: International journal of cancer. Volume 136:Issue 9(2015:May 01)
• Page Start: 2055
• Page End: 2064
• Publication Date: 2014-10-30
• Subjects: Cancer -- Periodicals; Cancer -- Prevention -- Periodicals; 616.994
• DOI: 10.1002/ijc.29269
• Languages: English
• ISSNs: 0020-7136

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <p>Bromodomain and extra terminal domain (BET) proteins are important epigenetic regulators facilitating the transcription of genes in chromatin areas linked to acetylated histones. JQ1, a BET protein inhibitor, has antiproliferative activity against many cancers, mainly through inhibition of c‐MYC and upregulation of p21. In this research, we investigated the use of JQ1 for human osteosarcoma (OS) treatment. JQ1 significantly inhibited the proliferation and survival of OS cells inducing G1 cell cycle arrest, premature senescence, but little effect on apoptosis. Interestingly, c‐MYC protein levels in JQ1‐treated cells remained unchanged, whereas the upregulation of p21 protein was still observable. Although effective <italic>in vitro</italic>, JQ1 alone failed to reduce the size of the MNNG/HOS xenografts in immunocompromised mice. To overcome the resistance of OS cells to JQ1 treatment, we combined JQ1 with rapamycin, an mammalian target of rapamycin (mTOR) inhibitor. JQ1 and rapamycin synergistically inhibited the growth and survival of OS cells <italic>in vitro</italic> and <italic>in vivo</italic>. We also identified that RUNX2 is a direct target of bromodomain‐containing protein 4 (BRD4) inhibition by JQ1 in OS cells. Chromatin immunoprecipitation (ChIP) showed that enrichment of BRD4 protein around RUNX2 transcription start sites diminished with JQ1 treatment in MNNG/HOS cells. Overexpression of RUNX2 protected JQ1‐sensitive OS cells from the effect of JQ1, and siRNA‐mediated inhibition of RUNX2 sensitized the same cells to JQ1. In conclusion, our findings suggest that JQ1, in combination with rapamycin, is an effective chemotherapeutic option for OS treatment. We also show that inhibition of RUNX2 expression by JQ1 partly explains the antiproliferative activity of JQ1 in OS cells.</p> </abstract>